World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
33938
World Ranking
13499
National Ranking
516

Overview

Giuseppe Tonini is affiliated with Università Campus Bio-Medico in Italy and specializes in the field of Medicine, with a strong emphasis on Oncology. Their research portfolio encompasses a range of subfields including Oncology, Pulmonary and Respiratory Medicine, Surgery, Cancer Research, and Molecular Biology.

Their research has contributed to several key topics in cancer study, notably:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Cholangiocarcinoma and Gallbladder Cancer Studies

Giuseppe Tonini's frequent publication venues include:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Cancers
  • ESMO Open
  • Precision Cancer Medicine

Several recent papers provide insight into the scope and focus of Tonini's research activities:

  • Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer, 2021, Annals of Oncology
  • Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial, 2023, The Lancet Oncology
  • The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials, 2020, British Journal of Cancer
  • Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples, 2020, Journal of Experimental & Clinical Cancer Research
  • Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study, 2020, Advances in Therapy

Giuseppe Tonini collaborates with several frequent co-authors, including:

  • Bruno Vincenzi
  • Daniele Santini
  • Francesco Pantano
  • Marco Russano
  • Alessio Cortellini

Best Publications

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

    Chiara Cremolini;Fotios Loupakis;Carlotta Antoniotti;Cristiana Lupi

  • Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

    Fotios Loupakis;Chiara Cremolini;Gianluca Masi;Sara Lonardi

  • Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr).

    E. Cacciari;S. Milani;Antonio Balsamo;E. Spada

  • KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

    F Loupakis;A Ruzzo;C Cremolini;B Vincenzi

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

    R. Gralla;M. Lichinitser;S. Van der Vegt;H. Sleeboom

  • Gut Microbiota and Cancer: From Pathogenesis to Therapy

    Silvia Vivarelli;Rossella Salemi;Saverio Candido;Luca Falzone

  • PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

    Fotios Loupakis;Luca Pollina;Irene Stasi;Annamaria Ruzzo

  • Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

    D. Miles;J. Gligorov;F. André;D. Cameron

  • Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients

    Daniele Santini;Bruno Vincenzi;Giordano Dicuonzo;Giuseppe Avvisati

  • Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study

    Paolo Maione;Francesco Perrone;Ciro Gallo;Luigi Manzione

  • Italian cross-sectional growth charts for height, weight and BMI (6-20 y).

    E Cacciari;S Milani;A Balsamo;F Dammacco

  • Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy

    Annamaria Ruzzo;Francesco Graziano;Fotios Loupakis;Eliana Rulli

  • Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study

    Maurizio Muscaritoli;Simone Lucia;Alessio Farcomeni;Vito Lorusso

  • Pamidronate Induces Modifications of Circulating Angiogenetic Factors in Cancer Patients

    Daniele Santini;Bruno Vincenzi;Giuseppe Avvisati;Giordano Dicuonzo

  • High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.

    Daniele Santini;Fotios Loupakis;Bruno Vincenzi;Irene Floriani

  • Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.

    T C Mineo;V Ambrogi;A Baldi;C Rabitti

  • Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

    Emanuele Valtorta;Cosimo Martino;Andrea Sartore-Bianchi;Frédérique Penaullt-Llorca

  • Pamidronate (P) induces modifications of circulating angiogenetic factors in cancer patients

    D. Santini;B. Vincenzi;G. Di Cuonzo;F. Battistoni

Frequent Co-Authors

Daniele Santini
Daniele Santini Università Campus Bio-Medico
Bruno Vincenzi
Bruno Vincenzi Università Campus Bio-Medico
Alfredo Falcone
Alfredo Falcone University of Pisa
Antonio Russo
Antonio Russo University of Palermo
Fotios Loupakis
Fotios Loupakis Istituto Oncologico Veneto
Stefano Cascinu
Stefano Cascinu Vita-Salute San Raffaele University
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Alfonso Baldi
Alfonso Baldi University of Campania "Luigi Vanvitelli"
Michele Caraglia
Michele Caraglia University of Campania "Luigi Vanvitelli"
Mauro Magnani
Mauro Magnani University of Urbino

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying medicine in the USA opens a variety of rewarding career pathways beyond traditional roles. Many students explore graduate-level healthcare degrees that can be completed online, offering flexibility and often lower costs.

If you're interested in mental health services, consider advancing your qualifications through online psych np programs. These programs prepare nurses for specialized, high-demand roles in psychiatric care.

For those fascinated by leadership and management in healthcare, obtaining a Master's in Healthcare Administration is a popular choice. You can find the cheapest mha programs online to help minimize educational expenses. Be sure to compare options carefully, as mha degree cost can vary significantly by institution.

Finally, advancing your nursing career with a Doctor of Nursing Practice is increasingly accessible. Explore the least expensive dnp programs to maximize your investment as you pursue top clinical leadership positions or influential roles in health policy.

Best Scientists Citing Giuseppe Tonini

Trending Scientists

Recently Published Articles